Investors

FGEN (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$32.75
Change (%) Stock is Up 0.50 (1.55%)
Volume509,497
Data as of 06/26/17 1:02 p.m. ET
Refresh quote
FibroGen is a research-based biotechnology company using its expertise in connective tissue growth factor (CTGF) and hypoxia-inducible factor (HIF) biology to discover, develop, and commercialize novel therapeutics for serious unmet medical needs.
Recent Press ReleasesMore »
DateTitle 
06/21/17FibroGen Granted Orphan Drug Designation for Pamrevlumab in the Treatment of Pancreatic CancerPrinter Friendly Version
06/13/17FibroGen to Present at the Goldman Sachs 38th Annual Global Healthcare ConferencePrinter Friendly Version
06/05/17European Patent Office Maintains FibroGen Patent Relating to Hypoxia-Inducible Factor (HIF) Prolyl Hydroxylase Inhibitor TechnologyPrinter Friendly Version
05/09/17FibroGen Reports First Quarter 2017 Financial ResultsPrinter Friendly Version
Upcoming EventsMore »
There are currently no events scheduled.
Data provided by Nasdaq. Minimum 15 minutes delayed. View Attributions and Sources